» Articles » PMID: 25980483

Common and Distinct Neural Effects of Risperidone and Olanzapine During Procedural Learning in Schizophrenia: a Randomised Longitudinal FMRI Study

Overview
Specialty Pharmacology
Date 2015 May 19
PMID 25980483
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Rationale: Most cognitive domains show only minimal improvement following typical or atypical antipsychotic treatments in schizophrenia, and some may even worsen. One domain that may worsen is procedural learning, an implicit memory function relying mainly on the integrity of the fronto-striatal system.

Objectives: We investigated whether switching to atypical antipsychotics would improve procedural learning and task-related neural activation in patients on typical antipsychotics. Furthermore, we explored the differential effects of the atypical antipsychotics risperidone and olanzapine.

Methods: Thirty schizophrenia patients underwent functional magnetic resonance imaging during a 5-min procedural (sequence) learning task on two occasions: at baseline and 7-8 weeks later. Of 30 patients, 10 remained on typical antipsychotics, and 20 were switched randomly in equal numbers to receive either olanzapine (10-20 mg) or risperidone (4-8 mg) for 7-8 weeks.

Results: At baseline, patients (all on typical antipsychotics) showed no procedural learning. At follow-up, patients who remained on typical antipsychotics continued to show a lack of procedural learning, whereas those switched to atypical antipsychotics displayed significant procedural learning (p = 0.001) and increased activation in the superior-middle frontal gyrus, anterior cingulate and striatum (cluster-corrected p < 0.05). These neural effects were present as a linear increase over five successive 30-s blocks of sequenced trials. A switch to either risperidone or olanzapine resulted in comparable performance but with both overlapping and distinct task-related activations.

Conclusions: Atypical antipsychotics restore procedural learning deficits and associated neural activity in schizophrenia. Furthermore, different atypical antipsychotics produce idiosyncratic task-related neural activations, and this specificity may contribute to their differential long-term clinical profiles.

Citing Articles

Adaptive coding of reward in schizophrenia, its change over time and relationship to apathy.

Kaliuzhna M, Carruzzo F, Kuenzi N, Tobler P, Kirschner M, Geffen T Brain. 2024; 147(7):2459-2470.

PMID: 38608149 PMC: 11224610. DOI: 10.1093/brain/awae112.


Modulation of hemispheric asymmetry in executive control of attention in schizophrenia with atypical antipsychotic treatment: Potential benefits of olanzapine.

Zhao Y, Li Y, Du J, Fang C, Li W, Lv M Schizophr Res Cogn. 2024; 36:100306.

PMID: 38469136 PMC: 10926294. DOI: 10.1016/j.scog.2024.100306.


Risperidone Reverses the Downregulation of BDNF in Hippocampal Neurons and MK801-Induced Cognitive Impairment in Rats.

Yu W, Zhu M, Fang H, Zhou J, Ye L, Bian W Front Behav Neurosci. 2019; 13:163.

PMID: 31396062 PMC: 6664152. DOI: 10.3389/fnbeh.2019.00163.


Superior effects of quetiapine compared with aripiprazole and iloperidone on MK-801-induced olfactory memory impairment in female mice.

Mutlu A, Mutlu O, Ulak G, Akar F, Kaya H, Erden F Biomed Rep. 2017; 6(5):567-570.

PMID: 28515915 PMC: 5431392. DOI: 10.3892/br.2017.879.


The neural underpinnings of cognitive flexibility and their disruption in psychotic illness.

Waltz J Neuroscience. 2016; 345:203-217.

PMID: 27282085 PMC: 5143214. DOI: 10.1016/j.neuroscience.2016.06.005.

References
1.
Keefe R, Sweeney J, Gu H, Hamer R, Perkins D, McEvoy J . Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007; 164(7):1061-71. DOI: 10.1176/ajp.2007.164.7.1061. View

2.
Meltzer H . What's atypical about atypical antipsychotic drugs?. Curr Opin Pharmacol. 2004; 4(1):53-7. DOI: 10.1016/j.coph.2003.09.010. View

3.
Geyer M, Vollenweider F . Serotonin research: contributions to understanding psychoses. Trends Pharmacol Sci. 2008; 29(9):445-53. DOI: 10.1016/j.tips.2008.06.006. View

4.
Heinrichs R . Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry. 2007; 64(6):631-2. DOI: 10.1001/archpsyc.64.6.631. View

5.
Kumari V, Gray J, Honey G, Soni W, Bullmore E, Williams S . Procedural learning in schizophrenia: a functional magnetic resonance imaging investigation. Schizophr Res. 2002; 57(1):97-107. DOI: 10.1016/s0920-9964(01)00270-5. View